RecruitingNot ApplicableNCT06098469

Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression


Sponsor

Centre Hospitalier Universitaire de Besancon

Enrollment

22 participants

Start Date

Oct 10, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The study evaluate the effect of 10 neurofeedback sessions on the residual symptoms of depressive patients in partial remission.


Eligibility

Min Age: 25 YearsMax Age: 65 Years

Inclusion Criteria7

  • Subjects aged 25 to 65 included
  • Information and signed informed consent
  • Patients with a diagnosis of major depressive episode in remission
  • MADRS score between 14 and 22
  • Patients with residual symptoms as assessed by MADRS items
  • No cognitive impairment.
  • Right-handed

Exclusion Criteria6

  • Subjects with legal incapacity or limited legal capacity
  • Subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
  • Pregnant women
  • Subjects in the exclusion period of another study or is on the "national volunteer list".
  • Subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia)
  • Subjects under a protective measure such as guardianship or safeguard of justice.

Interventions

DEVICENeurofeedback sessions

10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment


Locations(1)

CHU Besançon

Besançon, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06098469


Related Trials